SCHEMBL628640

SCHEMBL628640

Cc1ccc(S(=O)(=O)NC(Cc2ccccc2)C(=O)Cl)cc1

nearest known ligand 0.64

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
MMP9 P14780 9/20 0.64
TDP1 Q9NUW8 1/20 0.63
MMP2 P08253 9/20 0.63
ADAMTS4 O75173 1/20 0.63
ALDH1A1 P00352 2/20 0.60
ADAMTS5 Q9UNA0 1/20 0.60
MAPT P10636 1/20 0.60
POLB P06746 1/20 0.60
CTSL P07711 1/20 0.59
CA2 P00918 1/20 0.59
CA7 P43166 1/20 0.59
GAA P10253 1/20 0.56
MMP1 P03956 1/20 0.56
MMP3 P08254 1/20 0.56
MMP7 P09237 1/20 0.56
MMP13 P45452 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL628639 1.00 MMP9 (0.64) MMP9TDP1MMP2ADAMTS4ALDH1A1
SCHEMBL20601786 1.00 MMP9 (0.64) MMP9TDP1MMP2ADAMTS4ALDH1A1
SCHEMBL3856155 0.91 MMP2 (0.73) MMP9TDP1MMP2ADAMTS4ALDH1A1
SCHEMBL19450360 0.90 MMP2 (0.67) MMP9MMP2ADAMTS4ALDH1A1ADAMTS5
SCHEMBL433897 0.90 MMP2 (0.71) MMP9TDP1MMP2ADAMTS4ALDH1A1
SCHEMBL561565 0.90 MMP2 (0.71) MMP9TDP1MMP2ADAMTS4ALDH1A1
Chloromethane SCHEMBL7649372 0.89 MMP2 (0.75) MMP9TDP1MMP2ADAMTS4ALDH1A1
SCHEMBL697477 0.89 MMP2 (0.79) MMP9TDP1MMP2ADAMTS4ALDH1A1
SCHEMBL697476 0.89 MMP2 (0.79) MMP9TDP1MMP2ADAMTS4ALDH1A1
SCHEMBL1203540 0.89 MMP2 (0.79) MMP9TDP1MMP2ADAMTS4ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11760750-B1 Process for preparing levoketoconazole NURAY CHEMICALS PRIVATE LIMITED (IN) 2023-09-19 US claimed
US-20250051310-A1 BENZAZEPINE DERIVATIVES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2025-02-13 US disclosed
EP-4056557-B1 BENZAZEPINE DERIVATIVES USEFUL AS MEDICAMENTS OTSUKA PHARMA CO LTD (JP) 2023-11-22 EP disclosed
US-11760750-B1 Process for preparing levoketoconazole NURAY CHEMICALS PRIVATE LIMITED (IN) 2023-09-19 US disclosed
US-20230265073-A1 BENZAZEPINE DERIVATIVES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2023-08-24 US disclosed
US-11673878-B2 Benzazepine derivatives OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2023-06-13 US disclosed
US-20210078976-A1 BENZAZEPINE DERIVATIVES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2021-03-18 US disclosed
US-10889570-B2 Benzazepine derivatives OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2021-01-12 US disclosed
EP-3645513-A1 BENZAZEPINE DERIVATIVES Otsuka Pharmaceutical Co., Ltd. (JP) 2020-05-06 EP disclosed
CN-110891939-A Benzazepine derivatives 大塚制药株式会社 2020-03-17 CN disclosed
US-20130210857-A1 Inhibitors of Human Immunodeficiency Virus Replication BRISTOL-MYERS SQUIBB COMPANY (US) 2013-08-15 US disclosed
EP-1820503-B1 Aminoindazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions containing them PFIZER ITALIA SRL (IT) 2012-02-22 EP disclosed
EP-1432416-B1 AMINOINDAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM PFIZER ITALIA SRL (IT) 2011-01-19 EP disclosed
US-7511136-B2 Aminoindazole derivatives active as kinase inhibitors PFIZER ITALIA S.R.L. (IT) 2009-03-31 US disclosed
EP-1820503-A2 Aminoindazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions containing them Pfizer Italia S.r.l. (IT) 2007-08-22 EP disclosed
EP-1378507-B1 Process for producing optically active imidazole derivatives, intermediates and synthesis thereof MITSUBISHI PHARMA CORP (JP) 2006-08-23 EP disclosed
EP-1378507-A2 Process for producing optically active imidazole compounds, intermediates for synthesizing the same, and process for producing the same Mitsubishi Pharma Corporation (JP) 2004-01-07 EP disclosed
US-6166221-A Production method of optically active imidazole compound, synthetic intermediate therefor and production method thereof YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) 2000-12-26 US disclosed
US-6066739-A Process for producing optically active imidazole compounds, intermediates for synthesizing the same, and process for producing the same YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) 2000-05-23 US disclosed
EP-0972768-A1 PROCESS FOR PRODUCING OPTICALLY ACTIVE IMIDAZOLE COMPOUNDS, INTERMEDIATES FOR SYNTHESIZING THE SAME, AND PROCESS FOR PRODUCING THE SAME YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) 2000-01-19 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210078976-A1 BENZAZEPINE DERIVATIVES AVPR2, AVPR1A, AVPR1B MMP9 1806/4885TDP1 4462/4885MMP2 1796/4885
US-20230265073-A1 BENZAZEPINE DERIVATIVES AVPR2, AVPR1A, AVPR1B MMP9 1806/4885TDP1 4462/4885MMP2 1796/4885
US-11673878-B2 Benzazepine derivatives AVPR2, AVPR1A, AVPR1B MMP9 1806/4885TDP1 4462/4885MMP2 1796/4885
US-20250051310-A1 BENZAZEPINE DERIVATIVES AVPR2, AVPR1A, AVPR1B MMP9 1475/4885TDP1 4429/4885MMP2 1535/4885
US-20130210857-A1 Inhibitors of Human Immunodeficiency Virus Replication EIF2AK2, RTF2, MAVS MMP9 3516/4885TDP1 194/4885MMP2 3172/4885
US-10889570-B2 Benzazepine derivatives AVPR2, AVPR1A, AVPR1B MMP9 1806/4885TDP1 4462/4885MMP2 1796/4885
US-11760750-B1 Process for preparing levoketoconazole KHK, KYAT3, PLK3 MMP9 4204/4885TDP1 2147/4885MMP2 3614/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.